WebMar 1, 2024 · . Hopeful and excited for the 3 ongoing phase III studies with magro in frontline MDS and AML. A huge 🙏🏽 to all the patients, physicians and research teams helping make thes WebJun 4, 2024 · Christopher Hourigan speaks exclusively to VJHemOnc on acute myeloid leukemia therapeutics and transplantation. ... of the National Institutes of Health (NIH), …
Meet Our People Center for Cancer Research
WebProf Hourigan has an extensive research and industrial background in experimental and computational fluid dynamics, having been a National Research Council/NASA Research … WebDec 20, 2024 · PURPOSE Patients with acute myeloid leukemia (AML) in remission remain at risk for relapse even after allogeneic hematopoietic cell transplantation (alloHCT). AML measurable residual disease (MRD) status before alloHCT has been shown to be prognostic. Whether modulation of the intensity of the alloHCT conditioning regimen in … milwaukee to memphis tn
Suchitra Hourigan, M.D. NIH: National Institute of Allergy and ...
In 2024, Hourigan received a Presidential Early Career Award for Scientists and Engineers for his research on Measurable Residual Disease in Acute Myeloid Leukemia. In 2024, Hourigan was awarded the National Heart, Lung, and Blood Institute Orloff Award and honored for one of the top NIH accomplishments of 2024. WebDec 30, 2024 · Michael Heuser 1 , Sylvie D Freeman 2 , Gert J Ossenkoppele 3 , Francesco Buccisano 4 , Christopher S Hourigan 5 , Lok Lam Ngai 3 , Jesse M Tettero 3 , Costa Bachas 3 , Constance Baer 6 , Marie-Christine Béné 7 , Veit Bücklein 8 , Anna Czyz 9 , Barbara Denys 10 , Richard Dillon 11 , Michaela Feuring-Buske 12 , Monica L Guzman … WebMar 31, 2024 · Blood Test Identifies AML Patients at Greater Risk for Relapse After Transplant. NHLBI’s Dr. Chris Hourigan. Researchers at NIH showed the benefits of … milwaukee trick or treat times